Critically ill patients clearly face an increased risk for developing venous thromboembolic disease (VTE). Upon admission, all critical care patients should be immediately assessed for and prescribed VTE prophylaxis as it can significantly reduce VTE occurrence, its potential sequelae,and costs associated with VTE treatment. The financial burden associated with VTE is substantial. Longer ICU and hospital lengths of stay, pharmacy costs, and further outpatient management all contribute considerably to the economic burden of disease. The importance of this healthcare issue should motivate hospital administrators and physicians to systematically initiate thromboprophylaxis in all ICU patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ccc.2011.09.005 | DOI Listing |
Curr Opin Oncol
January 2025
Paris Cité University, Assistance-Publique-Hôpitaux de Paris (AP-HP), Service de Médecine Interne, Hôpital Louis-Mourier, Inserm, Paris Cardiovascular Research Center, Team « Endotheliopathy and Hemostasis Disorders », Paris, France.
Purpose Of Review: The life expectancy of patients suffering from thrombosis associated with cancer has improved significantly, making them a chronic disease. Patients with thrombosis and cancer are fragile. Treated with anticoagulants, they remain at risk of complications.
View Article and Find Full Text PDFPurpose: To evaluate longer term outcomes of the Zilver Vena Venous Stent in patients undergoing venous stenting.
Materials And Methods: Patients with iliofemoral obstructive venous disease and treated with venous stents were retrospectively enrolled in a physician-led real-world data collection effort. Results were analyzed by etiologies: post-thrombotic syndrome (PTS), non-thrombotic iliac vein lesion (NIVL), and iliocaval acute deep vein thrombosis (aDVT).
Cochrane Database Syst Rev
January 2025
Division of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Indiana University School of Medicine, Indianapolis, USA.
Background: People undergoing major orthopaedic surgery are at increased risk of postoperative thromboembolic events. Low molecular weight heparins (LMWHs) are recommended for thromboprophylaxis in this population. New oral anticoagulants, including direct factor Xa inhibitors, are recommended as alternatives.
View Article and Find Full Text PDFRes Pract Thromb Haemost
January 2025
Service de Médecine Vasculaire et Thérapeutique, Centre Hospitalo Universitaire de St-Etienne, Saint-Etienne, France.
Background: Rates of venous thromboembolism (VTE) recurrence and bleeding remain high in patients with cancer who are prescribed anticoagulants (ACs) such as low-molecular-weight heparin (LMWH) after an initial VTE event.
Objectives: To identify patient characteristics associated with VTE recurrence and bleeding in patients receiving LMWH for cancer-associated VTE and to explore secondary AC management and clinical outcomes in these patients.
Methods: An observational study was conducted using nationwide French data for adults with active cancer who were hospitalized with VTE in 2013-2018 and were reimbursed for LMWH ≤ 30 days after hospital discharge.
Blood Vessel Thromb Hemost
December 2024
Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!